微创穿刺血肿清除术联合血肿液化剂治疗脑出血研究进展OACSTPCD
Research Progress on the Treatment of Intracerebral Hemorrhage with Minimally Invasive Hematoma Aspiration Combined with Hematoma Liquefaction Agents
自发性脑出血是指脑实质内非创伤性血管破裂出血,其危害主要来自颅内血肿的占位效应及血肿周围脑组织继发性损害.随着外科手术技术的发展,自发性脑出血的治疗从传统的开颅手术向微创手术转变,已成为最具潜力的技术.微创穿刺血肿清除术治疗脑出血方便快捷、创伤小、安全有效且费用低廉,其中利用生化酶使血肿液化是该技术的核心之一,可安全快速清除血肿,有效改善患者预后.本文就微创穿刺血肿清除术联合血肿液化剂治疗脑出血的相关研究进展进行综述.
Spontaneous intracerebral hemorrhage(ICH)refers to non-traumatic vascular rupture and bleeding within the brain parenchyma.Its harm primarily stems from the space-occupying effect of the intracranial hematoma and secondary damage to the surrounding brain tissue.With the advancement of surgical techniques,the treatment of spontaneous ICH has shifted from traditional craniotomy to minimally invasive surgery(MIS),becoming one of the most promising technologies.MIS is fast,convenient,less traumatic,safe,effective,and cost-effective.One of the core aspects of this technique is the use of biochemical enzymes to liquefy the hematoma,allowing for safe and rapid removal of the hematoma and effectively improving patient outcomes.This article reviews the research progress on the treatment of ICH with MIS combined with hematoma liquefaction agents.
喻乙芳;马万宇;任思颖
贵州医科大学临床医学院 贵阳 550004贵州医科大学附属医院急诊神经科 贵阳 550004
临床医学
自发性脑出血微创穿刺血肿清除术尿激酶重组组织型纤溶酶原激活剂
spontaneous intracerebral hemorrhageminimally invasive surgeryurokinaserecombinant tissue plasminogen activator
《神经损伤与功能重建》 2024 (004)
222-226 / 5
国家自然科学基金项目(激活PPARã通过调控MTF1/CTR1通路抑制脑出血后神经元细胞铜死亡促进神经元突起再生修复的机制研究,No.82360253);贵州医科大学附属医院2021年博士科研启动基金(激活PPARã调控谷氨酸代谢促进小胶质细胞M2极化修复脑出血后血脑屏障的机制研究,No.gyfybsky-2021-30);贵州医科大学附属医院2021年度院级临床研究课题(内侧型小量丘脑出血"楔状征"对患者临床预后的影响,No.2021-GMHCT-016)
评论